On January 8, 2021, Gracell Biotechnologies Inc. (Nasdaq: GRCL) announced its initial public offering and listing of American depositary shares on the Nasdaq Global Market. The total offering size will be US$209 million prior to the exercise of the over-allotment option. Citigroup, Jefferies, Piper Sandler and Wells Fargo Securities acted as the joint bookrunners for this offering.
Gracell Biotechnologies is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies to address major industry challenges and fulfill unmet medical needs in the treatment of cancer. It aims to disrupt conventional approaches to CAR-T cell therapies with its proprietary technology platforms – FasTCAR and TruUCAR.
Zhong Lun Law Firm acted as the PRC legal advisor to the joint bookrunners in this offering. The legal team from Zhong Lun was led by Anthony Zhao, Catherine Chen William Jia and Shaun Gao, and included Roy Zheng, Edward Zhou, etc.